-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
-
Summary
-
Revance Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q1 2014 to Q1 2024.
- Revance Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2024 was -$65.9M, a 5.12% increase year-over-year.
- Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$217M, a 11.9% decline from 2022.
- Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$194M, a 12.6% increase from 2021.
- Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was -$222M, a 24.1% decline from 2020.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)